Related Experiment Video
Updated: Jul 16, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Anticoagulation in atrial fibrillation: a contemporary viewpoint
1Libin Cardiovascular Institute of Alberta, University of Calgary, and Calgary Health Region, Calgary, Alberta, Canada. dgwyse@ucalgary.ca
Heart Rhythm
|March 6, 2007
Summary
Anticoagulation therapy for atrial fibrillation balances stroke risk and bleeding. This review covers chronic treatment, cardioversion, and ablation, highlighting the need for better risk assessment and warfarin alternatives.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) necessitates anticoagulation to prevent stroke.
- Current guidelines (e.g., ACC/AHA/ESC) offer risk stratification for chronic anticoagulation.
- Balancing antithrombotic benefits against bleeding risks is crucial.
Purpose of the Study:
- To review current anticoagulation strategies in AF patients.
- To discuss controversies and emerging data regarding anticoagulation.
- To identify areas for future research in AF anticoagulation.
Main Methods:
- Review of existing literature and guidelines on anticoagulation in AF.
- Analysis of risk stratification schemes and bleeding risk factors.
- Discussion of anticoagulation protocols for cardioversion and ablation.
Main Results:
- Existing risk stratification schemes for chronic anticoagulation vary.
- Hypertension and AF type (paroxysmal vs. continuous) are discussed as potential risk factors.
- Data on bleeding risk with vitamin K antagonists, especially in the elderly, is evolving.
- Alternatives to warfarin have faced recent study failures.
Conclusions:
- Anticoagulation management in AF requires careful benefit-risk assessment.
- Further research is needed to simplify risk stratification and develop safer alternatives to warfarin.
- Long-term anticoagulation may be indicated post-left atrial radiofrequency ablation for high-risk patients.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...